Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay

Fig. 6

Brevilin A significantly inhibits CRC growth in vivo. A Representative images of tumors. B–E Tumor volume (B), tumor weights (C), body weights (D) and organ index (E) of mice. After subcutaneous inoculation of CT26 cells, mice were randomly divided into 3 groups of 6 each: vehicle (30% PEG-400/5% Tween-80 solution), 4 mg/kg of brevilin A and 8 mg/kg of brevilin A groups. F TUNEL staining of the tumors in each group. G, H IHC staining of cleaved-Caspase 3 (G) and Ki67 (H) in the tumor tissues; and quantitative results were shown in the (right panel). n = 6. Data are presented as mean ± SD, **P < 0.01, *P < 0.05 vs. model group

Back to article page